Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease (2017)
- Authors:
- Lincoff, A. Michael
- Nicholls, Stephen J.
- Riesmeyer, Jeffrey S.
- Barter, Philip J.
- Brewer, H. Bryan
- Fox, Keith A.A.
- Gibson, C. Michael
- Granger, Christopher
- Menon, Venu
- Montalescot, Gilles
- Rader, Daniel
- Tall, Alan R.
- McErlean, Ellen
- Wolski, Kathy
- Ruotolo, Giacomo
- Vangerow, Burkhard
- Weerakkody, Govinda
- Goodman, Shaun G.
- Conde, Diego
- McGuire, Darren K.
- Nicolau, Jose C.
- Leiva-Pons, Jose L.
- Pesant, Yves
- Li, Weimin
- Kandath, David
- Kouz, Simon
- Tahirkheli, Naeem
- Mason, Denise
- Nissen, Steven E.
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1056/NEJMoa1609581
- Subjects: FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO; COLESTEROL; DOENÇAS CARDIOVASCULARES; ESTUDOS RANDOMIZADOS
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: The New England Journal of Medicine
- ISSN: 0028-4793
- Volume/Número/Paginação/Ano: v. 376, n. 20, p. 1933-1942, 2017
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
LINCOFF, A. Michael; NICHOLLS, Stephen J.; RIESMEYER, Jeffrey S.; et al. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. The New England Journal of Medicine, Boston, v. 376, n. 20, p. 1933-1942, 2017. Disponível em: < http://www.nejm.org/doi/pdf/10.1056/NEJMoa1609581 > DOI: 10.1056/NEJMoa1609581. -
APA
Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., et al. (2017). Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. The New England Journal of Medicine, 376( 20), 1933-1942. doi:10.1056/NEJMoa1609581 -
NLM
Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease [Internet]. The New England Journal of Medicine. 2017 ; 376( 20): 1933-1942.Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1609581 -
Vancouver
Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease [Internet]. The New England Journal of Medicine. 2017 ; 376( 20): 1933-1942.Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1609581 - Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
- Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
- High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
- Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery: Results From the PLATO (Platelet Inhibition and Patient Outcomes) Trial
- Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction
Informações sobre o DOI: 10.1056/NEJMoa1609581 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
